What tigecycline dosing regimen should be used for an adult with decompensated chronic liver disease (Child‑Pugh class C) infected with carbapenem‑resistant Acinetobacter baumannii?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Tigecycline Dosing for CRAB in Child-Pugh C Cirrhosis

For a patient with decompensated cirrhosis (Child-Pugh C) and CRAB infection, use tigecycline 100 mg loading dose followed by 25 mg every 12 hours, always in combination with another active agent.

FDA-Mandated Dose Reduction

The FDA drug label explicitly requires dose reduction in Child-Pugh C patients 1. After the standard 100 mg loading dose, the maintenance dose must be reduced to 25 mg every 12 hours (half the standard 50 mg dose). This is the only FDA-approved dosing adjustment for any patient population and takes precedence over all other considerations.

Critical Context: High-Dose Tigecycline and Liver Disease

While high-dose tigecycline (200 mg loading, then 100 mg q12h) has been used successfully for severe CRAB infections in ICU patients 2, 3, this approach is contraindicated in Child-Pugh C patients. Recent evidence demonstrates that:

  • Standard-dose tigecycline (50 mg q12h) achieved superior outcomes compared to high-dose in liver failure patients, with better microbial eradication and fewer adverse events 4
  • High-dose tigecycline in Child-Pugh C patients increased mortality risk (HR 1.85) and caused significantly more hepatotoxicity, coagulopathy, and thrombocytopenia 4
  • The reduced dose (25 mg q12h) in Child-Pugh C patients produces AUC exposures equivalent to high-dose tigecycline in non-cirrhotic patients 5

Common pitfall: Attempting to use high-dose tigecycline for severe CRAB infection in cirrhotic patients. The pharmacokinetic data clearly show that tigecycline clearance is already profoundly reduced in critically ill patients with liver disease (8.6 L/h vs normal 21-24 L/h) 5. The 25 mg q12h dose in Child-Pugh C achieves therapeutic exposures without excessive toxicity.

Mandatory Combination Therapy

Tigecycline must never be used as monotherapy for CRAB infections 2. The 2015 ICU Task Force guidelines explicitly state: "Due to the uncertainties about the efficacy of tigecycline in non-approved indications, we recommend its use in combination with another active agent, if possible" 2.

Preferred combination partners (if susceptible):

  • Polymyxin B (1.5-3 mg/kg/day; no dose adjustment needed for liver disease) 2
  • Sulbactam (9-12 g/day if MIC ≤4 mg/L; may be preferable to preserve polymyxins) 2
  • Colistin (loading dose 6-9 million IU, then 4.5 million IU q12h, adjusted for renal function) 2

Infection Site Considerations

Tigecycline has poor serum concentrations and should be avoided for CRAB bacteremia 2. It achieves adequate tissue penetration for:

  • Complicated intra-abdominal infections (FDA-approved indication) 1
  • Complicated skin/soft tissue infections (FDA-approved indication) 1
  • Pneumonia (off-label, requires combination therapy) 2

For CRAB pneumonia specifically: Even with dose reduction, tigecycline can be effective when combined with another active agent, as the MIC threshold of ≤1 mg/L remains achievable 2. However, clinical success depends heavily on source control and overall disease severity rather than drug exposure alone 5.

Monitoring Requirements

Patients with Child-Pugh C receiving tigecycline require:

  • Close monitoring for treatment response (clinical improvement should be evident within 7 days) 4
  • Surveillance for hepatotoxicity (transaminases, bilirubin)
  • Coagulation parameters (fibrinogen, PT/INR)
  • Platelet counts
  • Renal function (tigecycline can cause azotemia)

Duration: 7-14 days for pneumonia, 5-14 days for intra-abdominal or skin infections, guided by clinical response 1.

When Tigecycline May Not Be Appropriate

Consider alternative agents first if available:

  • Sulbactam-durlobactam (if susceptible and available) 6
  • Cefiderocol (if susceptible) 6
  • Polymyxin-based combinations without tigecycline 7

The 2022 Taiwan guidelines note that tigecycline for CRE (not specifically CRAB) uses standard dosing of 100 mg loading then 50 mg q12h 8, but these recommendations do not address Child-Pugh C patients where FDA labeling mandates dose reduction.

Related Questions

What is the appropriate tigecycline dosing regimen for infants with carbapenem‑resistant Acinetobacter baumannii infection?
Is tigecycline appropriate for treating an Escherichia coli infection, and what is the recommended dosing regimen?
What loading dose does the Infectious Diseases Society of America (IDSA) 2026 edition recommend for tigecycline?
How should tigecycline be administered intravenously, including dosing, infusion duration, and adjustments for hepatic impairment and pediatric patients?
What are the considerations for using tigecycline (generic name) in patients with acute kidney injury (Impaired renal function)?
In a 60-year-old man with a moderate-to-large bilateral pulmonary embolism and preserved right‑ventricular function, could the clot have resolved spontaneously without hospital treatment?
What could be causing the elevated aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin in a patient after ERCP with stone extraction and biliary stent placement who is receiving ceftriaxone?
For Candida auris infection resistant to amphotericin B and fluconazole, what is the recommended caspofungin dosing regimen and duration of therapy?
Can meloxicam cause microscopic hematuria?
Why should HIV and RPR (syphilis) testing be performed at gestational age 28 weeks?
What are the benefits of using a higher inspiratory positive airway pressure (IPAP) with a relatively low expiratory positive airway pressure (EPAP), such as settings of 12 cm H₂O/5 cm H₂O or 15 cm H₂O/5 cm H₂O?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.